NCT06097663View on ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)

PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 15, 2024

Primary Completion Date

October 27, 2024

Study Completion Date

November 4, 2024

Conditions
Coronary Heart DiseaseClonal Hematopoiesis of Indeterminate Potential (CHIP)
Interventions
DRUG

MAS825

Active MAS825 single dose

DRUG

MAS825 Placebo

MAS825 placebo single dose

DRUG

DFV890

Oral tablet of DFV890 active once daily

DRUG

DFV890 placebo

Oral tablet of DFV890 placebo once daily

Trial Locations (6)

53105

Novartis Investigative Site, Bonn

60590

Novartis Investigative Site, Frankfurt

63110

Washington University, St Louis

80636

Novartis Investigative Site, München

37232-8805

Vanderbilt University Medical Cent, Nashville

H1T 1C8

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY